|
1
|
Kholodenko IV, Kalinovsky DV, Doronin II,
Deyev SM and Kholodenko RV: Neuroblastoma origin and therapeutic
targets for immunotherapy. J Immunol Res. 2018:3942682018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park JR, Eggert A and Caron H:
Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol
Clin North Am. 24:65–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nong J, Su C, Li C, Wang C, Li W, Li Y,
Chen P, Li Y, Li Z, She X, et al: Global, regional, and national
epidemiology of childhood neuroblastoma (1990–2021): A statistical
analysis of incidence, mortality, and DALYs. EClinicalMedicine.
79:1029642025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith V and Foster J: High-risk
neuroblastoma treatment review. Children (Basel).
5:1142018.PubMed/NCBI
|
|
5
|
Su Y, Qin H, Chen C, Wang S, Zhang S,
Zhang D, Jin M, Peng Y, He L, Wang X, et al: Treatment and outcomes
of 1041 pediatric patients with neuroblastoma who received
multidisciplinary care in China. Pediatr Investig. 4:157–167. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
London WB, Castel V, Monclair T, Ambros
PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL,
Iehara T and Matthay KK: Clinical and biologic features predictive
of survival after relapse of neuroblastoma: A report from the
international neuroblastoma risk group project. J Clin Oncol.
29:3286–3292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Medical Products Administration,
. Information on the pending collection of drug approval documents
released on August 16, 2021. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210816154622110.htmlMay
5–2025
|
|
8
|
National Comprehensive Cancer Network.
Clinical Practice Guidelines in Oncology, . Neuroblastoma. Version
2.2024. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/neuroblastoma.pdfMay
5–2025
|
|
9
|
Gray J, Moreno L, Weston R, Barone G,
Rubio A, Makin G, Vaidya S and Wheatley W: BEACON-Immuno: Results
of the dinutuximab beta (dB) randomization of the
BEACON-Neuroblastoma phase 2 trial-A european innovative therapies
for children with cancer (ITCC-International Society of Paediatric
Oncology Europe Neuroblastoma Group (SIOPEN) trial. J Clin Oncol.
40:10002. 2022. View Article : Google Scholar
|
|
10
|
Mody R, Yu AL, Naranjo A, Zhang FF, London
WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, et
al: Irinotecan, temozolomide, and dinutuximab with GM-CSF in
children with refractory or relapsed neuroblastoma: A report from
the Children's oncology group. J Clin Oncol. 38:2160–2169. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olgun N, Arayici ME, Kızmazoglu D and
Cecen RE: Assessment of Chemo-immunotherapy regimens in patients
with refractory or relapsed neuroblastoma: A systematic review with
Meta-analysis of critical oncological outcomes. J Clin Med.
14:9342025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wieczorek A, Zaniewska-Tekieli A, Ehlert
K, Pawinska-Wasikowska K, Balwierz W and Lode H: Dinutuximab beta
combined with chemotherapy in patients with relapsed or refractory
neuroblastoma. Front Oncol. 13:10827712023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Monclair T, Brodeur GM, Ambros PF, Brisse
HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK,
Nuchtern JG, et al: The international neuroblastoma risk group
(INRG) staging system: An INRG task force report. J Clin Oncol.
27:298–303. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park JR, Bagatell R, Cohn SL, Pearson AD,
Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K,
Nuchtern JG, et al: Revisions to the international neuroblastoma
response criteria: A consensus statement from the national cancer
institute clinical trials planning meeting. J Clin Oncol.
35:2580–2587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pauwels E, Cleeren F, Tshibangu T, Koole
M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K,
Bormans G and Deroose CM: [18F]AlF-NOTA-octreotide PET imaging:
biodistribution, dosimetry and first comparison with
[68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med
Mol Imaging. 47:3033–3046. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hou J, Long T, He Z, Zhou M, Yang N, Chen
D, Zeng S and Hu S: Evaluation of 18F-AlF-NOTA-octreotide for
imaging neuroendocrine neoplasms: Comparison with 68Ga-DOTATATE
PET/CT. EJNMMI Res. 11:552021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events (CTCAE)
Version 5.0. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5×7.pdfOctober
15–2025
|
|
18
|
European Medicines Agency, . Qarziba
epar-product information. https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en.pdfOctober
15–2025
|
|
19
|
Olgun N, Cecen E, Ince D, Kizmazoglu D,
Baysal B, Onal A, Ozdogan O, Guleryuz H, Cetingoz R, Demiral A, et
al: Dinutuximab beta plus conventional chemotherapy for
relapsed/refractory high-risk neuroblastoma: A single-center
experience. Front Oncol. 12:10414432022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mody R, Naranjo A, Van Ryn C, Yu AL,
London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel
PM, et al: Irinotecan-temozolomide with temsirolimus or dinutuximab
in children with refractory or relapsed neuroblastoma (COG
ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol.
18:946–957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Troschke-Meurer S, Zumpe M, Meißner L,
Siebert N, Grabarczyk P, Forkel H, Maletzki C, Bekeschus S and Lode
HN: Chemotherapeutics used for High-risk neuroblastoma therapy
improve the efficacy of Anti-GD2 antibody dinutuximab beta in
preclinical spheroid models. Cancers (Basel). 15:9042023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Raiser P, Schleiermacher G, Gambart M,
Dumont B, Defachelles AS, Thebaud E, Tandonnet J, Pasqualini C,
Proust S, Entz-Werle N, et al: Chemo-immunotherapy with dinutuximab
beta in patients with relapsed/progressive high-risk neuroblastoma:
Does chemotherapy backbone matter? Eur J Cancer. 202:1140012024.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ladenstein R, Pötschger U, Valteau-Couanet
D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM,
Owens C, et al: Interleukin 2 with anti-GD2 antibody ch14.18/CHO
(dinutuximab beta) in patients with high-risk neuroblastoma
(HR-NBL1/SIOPEN): A multicentre, randomised, phase 3 trial. Lancet
Oncol. 19:1617–1629. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ladenstein RL, Poetschger U,
Valteau-Couanet D, Gray J, Luksch R, Balwierz W, Castel V and Lode
HN: Randomization of dose-reduced subcutaneous interleukin-2
(scIL2) in maintenance immunotherapy (IT) with anti-GD2
antibody dinutuximab beta (DB) long-term infusion (LTI) in
front-line high-risk neuroblastoma patients: Early results from the
HR-NBL1/SIOPEN trial. J Clin Oncol. 37:10013. 2019. View Article : Google Scholar
|
|
25
|
Lode HN, Ladenstein R, Troschke-Meurer S,
Struppe L, Siebert N, Zumpe M, Ehlert K, Huber S, Glogova E,
Hundsdoerfer P, et al: Effect and tolerance of N5 and N6
chemotherapy cycles in combination with dinutuximab beta in
relapsed High-risk neuroblastoma patients who failed at least one
second-line therapy. Cancers (Basel). 15:33642023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barone G, Barry A, Bautista F, Brichard B,
Defachelles AS, Herd F, Manzitti C, Reinhardt D, Rubio PM,
Wieczorek A and van Noesel MM: Managing adverse events associated
with dinutuximab beta treatment in patients with High-risk
neuroblastoma: Practical guidance. Pediatr Drugs. 23:537–548. 2021.
View Article : Google Scholar
|
